5L6Y

il13 in complex with tralokinumab

5L6Y の概要

• エントリーDOI: 10.2210/pdb5l6y/pdb
• 分子名称: Interleukin-13, tralokinumab FAb digest VH, tralokiumab FAb digest VL, ... (5 entities in total)
• 機能のキーワード: il13 antibody tralokinumab asthma, il13, immune system
• 由来する生物種: Homo sapiens (Human); 詳細
• 細胞内の位置: Secreted: P35225
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 61067.11

構造登録者

Breed, J. (登録日: 2016-06-01, 公開日: 2016-12-21, 最終更新日: 2024-10-23)

主引用文献

Popovic, B.,Breed, J.,Rees, D.G.,Gardener, M.J.,Vinall, L.M.,Kemp, B.,Spooner, J.,Keen, J.,Minter, R.,Uddin, F.,Colice, G.,Wilkinson, T.,Vaughan, T.,May, R.D.
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13R alpha 1 and IL-13R alpha 2.
J. Mol. Biol., 429:208-219, 2017

PubMed Abstract: Interleukin (IL)-13 is a pleiotropic T helper type 2 cytokine frequently associated with asthma and atopic dermatitis. IL-13-mediated signalling is initiated by binding to IL-13Rα1, which then recruits IL-4Rα to form a heterodimeric receptor complex. IL-13 also binds to IL-13Rα2, considered as either a decoy or a key mediator of fibrosis. IL-13-neutralising antibodies act by preventing IL-13 binding to IL-13Rα1, IL-4Rα and/or IL-13Rα2. Tralokinumab (CAT-354) is an IL-13-neutralising human IgG4 monoclonal antibody that has shown clinical benefit in patients with asthma. To decipher how tralokinumab inhibits the effects of IL-13, we determined the structure of tralokinumab Fab in complex with human IL-13 to 2 Å resolution. The structure analysis reveals that tralokinumab prevents IL-13 from binding to both IL-13Rα1 and IL-13Rα2. This is supported by biochemical ligand-receptor interaction assay data. The tralokinumab epitope is mainly composed of residues in helices D and A of IL-13. It is mostly light chain complementarity-determining regions that are driving paratope interactions; the variable light complementarity-determining region 2 plays a key role by providing residue contacts for a network of hydrogen bonds and a salt bridge in the core of binding. The key residues within the paratope contributing to binding were identified as Asp50, Asp51, Ser30 and Lys31. This study demonstrates that tralokinumab prevents the IL-13 pharmacodynamic effect by binding to IL-13 helices A and D, thus preventing IL-13 from interacting with IL-13Rα1 and IL-13Rα2.

PubMed: 27956146
DOI: 10.1016/j.jmb.2016.12.005

実験手法

X-RAY DIFFRACTION (1.99 Å)